Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma

Cancer

Volumn 100, Issue 11, 2004, Pages 2408-2414

  Rizzieri, David A ^a   Sand, Gregory J ^a   McGaughey, Dean ^a   Moore, Joseph O ^a   DeCastro, Carlos ^a   Chao, Nelson J ^a   Vredenburgh, James J ^a   Gasparetto, Cristina ^a   Long, Gwynn D ^a   Anderson, Elizabeth ^a   Foster, Tracy ^a   Toaso, Bonnie ^a   Adams, Donna ^a   Niedzwiecki, Donna ^a   Gockerman, Jon P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Non Hodgkin lymphoma (NHL); Paclitaxel; Recurrent; Refractory; Response

Indexed keywords

CIMETIDINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; ETOPOSIDE; PACLITAXEL; PREDNISONE; TAXANE DERIVATIVE; VASCULOTROPIN; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FEMALE; HUMAN; MALE; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RECURRENT CANCER; SEPSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; FEMALE; HUMANS; LYMPHOMA, MANTLE-CELL; LYMPHOMA, NON-HODGKIN; MALE; MAXIMUM TOLERATED DOSE; MICROCIRCULATION; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; REMISSION INDUCTION; SALVAGE THERAPY;

EID: 2442664363     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20245     Document Type: Article

References (20)

1. Philip T, Chauvin F, Bron D, et al. PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients). Ann Oncol. 1991;2:57-64.
2. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer. 1982; 49:2112-2135.
3. Guchelaar HJ, ten Napel CH, de Vries EG, et al. Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug Taxol: a review. Clin Oncol. 1994;6:40-48.
4. Nitta M, Tsuiki H, Arima Y, et al. Hyperploidy induced by drugs that inhibit formation of microtubule promotes chromosome instability. Genes Cells. 2002;7:151-162.
5. Cowan KH, Moscow JA, Huang H, et al. Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. Clin Cancer Res. 1999;5:1619-1628.
6. Chen Q, Zhang QZ, Liu J, et al. Multi-center prospective randomized trial on paclitaxel liposome and traditional taxol in the treatment of breast cancer and non-small-cell lung cancer [in Chinese]. Zhonghua Zhong Liu Za Zhi. 2003; 25:190-192.
7. Klauber N, Parangi S, Flynn E, et al. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and Taxol. Cancer Res. 1997;13:81-86.
8. Vacca A, Ribatti D, Iurlaro M, et al. Docetaxel versus paclitaxel for antiangiogenesis. J Hematother Stem Cell Res. 2002; 11:103-118.
9. Ribatti D, Vacca A, Nico B, et al. Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study. Eur J Haematol. 1996;56:45-53.
10. Vacca A, Ribatti D, Fanelli M, et al. Expression of tenascin is related to histologic malignancy and angiogenesis in B-cell non-Hodgkin's lymphomas. Leuk Lymphoma. 1996;22:473-481.
11. Rizzieri DA, Wikstrand CJ, Mann K, et al. Markers of angiogenesis, factor VIII and tenascin, correlate with disease activity in patients with non-Hodgkin's lymphoma. Blood. 1999;94(Suppl 1):4339.
12. Harris N, Jaffe E, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84: 1361-1392.
13. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244-1253.
14. National Cancer Institute Cancer Therapy Evaluation Program. Hematological toxicities. In: Common terminology criteria for adverse events, version 3.0. Washington, DC: DCTD, NCI, NIH, and DHHS, 2003:4. Available from URL: http://ctep.cancer.gov [accessed 31 March 20031.
15. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 1993;93:3064-3073.
16. Ribatti D, Vacca A, Marzullo A, Nico B, Ria R, Roncali L. Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Int J Cancer. 2000;85: 171-175.
17. Pruneri G, Ponzoni M, Ferreri AJ, et al. Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Haematol. 2000; 118:817-820.
18. Press OW, LeBlanc M, O'Rourke TJ, et al. Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas. Southwest Oncology Group trial 9246. J Clin Oncol. 1998;16:574-578.
19. Casasnovas RO, Haioun C, Dumontet C, et al. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Haematologica. 2000;85:502-507.
20. Lichtman SM, Niedzwiecki D, Barcos et al. Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B. Ann Oncol. 2000;11:1141-1146.